Hypothesis

Precision correction of prevalent mitochondrial DNA heteroplasmies using mitochondria‑targeted CRISPR base editors will attenuate cytosolic mtDNA‑derived danger signals, thereby suppressing both NLRP3 inflammasome and cGAS‑STING pathways and reversing T‑cell exhaustion in aged mammals.

Mechanistic Rationale

The seed work shows that oxidized mtDNA acts as a DAMP that fuels NF‑κB/NLRP3 inflammasome activation, driving chronic cytokine release and T‑cell dysfunction [1]. Beyond NLRP3, cytosolic mtDNA also engages the cGAS‑STING sensor, leading to type I interferon production that can exacerbate exhaustion phenotypes [2]. Heteroplasmic mtDNA mutations increase mitochondrial ROS and promote the release of both DNA and RNA fragments; the latter can act as endogenous ligands for endosomal TLR7/8, further amplifying NF‑κB signaling independent of inflammasome assembly [3]. By editing the most pathogenic heteroplasmic sites (e.g., m.3243A>G, m.8344A>G) we anticipate a drop in mtROS, a reduction in liberated mtDNA/mtRNA, and consequently diminished signaling through NLRP3, cGAS‑STING, and TLR7/8 axes. This should restore mitochondrial respiration, lower HIF‑1α stabilization, and allow exhausted T‑cells to regain proliferative capacity and effector cytokine production [4].

Experimental Design

1. Model: C57BL/6 mice aged 20 months, exhibiting ~5‑fold increase in somatic mtDNA mutations [5].
2. Intervention: AAV9 vector conjugated to a mitochondria‑targeting signal (MTS) delivering a cytosine base editor (e.g., DdCBE) programmed to correct the m.3243A>G heteroplasmy. Control groups receive AAV9‑MTS‑GFP or empty vector.
3. Readouts (at 4, 8, and 12 weeks post‑treatment):
   • Quantify heteroplasmy shift by duplex sequencing.
   • Measure cytosolic mtDNA levels (qPCR of cytosolic fraction).
   • Assess NLRP3 activation (caspase‑1 p20, IL‑1β ELISA) and cGAS‑STING activation (phospho‑TBK1, IFN‑β) in splenic CD8⁺ T cells.
   • Flow cytometry for exhaustion markers (PD‑1, TIM‑3, LAG‑3) and cytokine production (IFN‑γ, TNF‑α) after ex‑vivo stimulation.
   • Seahorse analysis of mitochondrial respiration (OCR, ECAR).
   • Survival and frailty index monitoring over 6 months.

Expected Outcomes

• A significant reduction (>30 %) in m.3243A>G heteroplasmy in treated mice.
• Corresponding decrease in cytosolic mtDNA and mtRNA, leading to lowered NLRP3 inflammasome and cGAS‑STING activity.
• Restoration of T‑cell proliferative capacity and effector cytokine production, with exhaustion marker expression dropping to levels seen in 6‑month‑old controls.
• Improved mitochondrial respiration and delayed onset of frailty, extending median healthspan by ~15 %.

Potential Pitfalls

• Off‑target editing of nuclear genome could confound results; we will include whole‑genome sequencing of edited tissues to verify specificity.
• Mitochondrial base editing efficiency may be low in post‑mitotic tissues; alternating delivery with a mitotropic peptide‑PNA could enhance uptake.
• Compensatory pathways (e.g., AIM2 inflammasome) might persist; we will monitor caspase‑1 activation via alternative stimuli.

If the hypothesis holds, it would demonstrate that the mitochondrial genome is not a passive bystander but a driver of immunosenescence, and that precise mtDNA editing can uncouple aging from immune dysfunction.